Phaseline

Companies › Henan Genuine Biotech

Henan Genuine Biotech: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 5 Phase 1, 1 Phase 2; Oncology, Genitourinary, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CL-197 capsules
HIV-1 antiretroviral agent
–Phase 2HIV-1 InfectionDec 2026
GEN-725
EGFR tyrosine kinase inhibitor
EGFRPhase 1Advanced Solid Tumors; Non-Small Cell Lung CancerDec 2026
Dositinib mesylate tablets (90-1408)
EGFR inhibitor
EGFRPhase 1Non-Small Cell Lung CancerDec 2027
Ro-0622
Reverse transcriptase inhibitor; Replicase polyprotein 1ab inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLR2APhase 1Renal Insufficiency–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07001436Ro-0622Phase 1Renal InsufficiencyGenitourinaryAug 2025
NCT07308782CL-197 capsulesPhase 2HIV-1 InfectionInfectious diseaseDec 2026
NCT07229898GEN-725Phase 1Advanced Solid TumorsOncologyDec 2026
NCT07362940GEN-725Phase 1Non-Small Cell Lung CancerOncologyJul 2027
NCT07362940GEN-725Phase 1Non-Small Cell Lung CancerOncologyJul 2027
NCT07231068Dositinib mesylate tablets (90-1408)Phase 1Non-Small Cell Lung CancerOncologyDec 2027

Targets

EGFR (2) POLR2A (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Jiangsu Hansoh Pharmaceutical Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical Jiangsu Alphamab Biopharmaceuticals HC Biopharma ArriVent BioPharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.